staurosporine has been researched along with Myelodysplastic Syndromes in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Angelopoulou, MK; Chatzidimitriou, C; Konstantopoulos, K; Korkolopoulou, P; Lafioniatis, S; Lakiotaki, E; Pappa, V; Plata, E; Vassilakopoulos, TP | 1 |
| Mueller, BU; Pabst, T; Seipel, K | 1 |
| Baer, MR; Bauer, KS; Carroll, M; Fleckinger, S; Gojo, I; Luger, S; Norsworthy, KJ; Perl, A; Sausville, EA; Tidwell, M | 1 |
| Andreeff, M; Borthakur, G; Cortes, J; Daver, N; Durand, M; Estrov, Z; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Rajkhowa, T; Ravandi, F; Strati, P | 1 |
| Deangelo, DJ; Dutreix, C; Ehninger, G; Estey, E; Feldman, EJ; Fischer, T; Fox, E; Galinsky, I; Giles, FJ; Gilliland, DG; Huntsman-Labed, A; Klimek, VM; Lanza, C; Nimer, SD; Schiller, GJ; Stone, RM; Virkus, J | 1 |
2 review(s) available for staurosporine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Myelodysplastic syndromes and acute myeloid leukemias in the elderly.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Gemtuzumab; Geriatric Assessment; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Staurosporine | 2018 |
3 trial(s) available for staurosporine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Treatment Outcome; Young Adult | 2013 |
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Staurosporine; Young Adult | 2015 |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Receptor Protein-Tyrosine Kinases; Staurosporine; Treatment Outcome | 2010 |
1 other study(ies) available for staurosporine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blood Cell Count; Bone Marrow; Cancer Survivors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Diagnosis, Differential; Eosinophilia; Hemorrhagic Disorders; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine; Tryptases | 2021 |